Pathologic complete response after first-line tislelizumab, cetuximab, and dabrafenib in microsatellite-stable BRAF V600E-mutant metastatic colorectal cancer: a case report. (PubMed, Anticancer Drugs) - Oct 7, 2026 - "This case highlights the possibility that selected patients with MSS, BRAF V600E-mutant mCRC may achieve durable remission with combined programmed cell death protein 1 blockade and dual-targeted therapy. The observed association between high intratumoral CD8+ T-cell infiltration, elevated PD-L1 expression, and favorable treatment response should be considered hypothesis-generating and requires validation in prospective biomarker-driven studies."
IO biomarker • Journal • Colon Adenocarcinoma • Colon Cancer • Colorectal Adenocarcinoma • Colorectal Cancer • Oncology • Solid Tumor • BRAF • CD8 • PD-1 • PD-L1
|
|
Jiangyan Guo; Junyi Qian; Liyao Xiao; Mingjin Wu; Rong Li; Rui Li; Xuan Zhang; Ya Zhang; Yanping Lin
|